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HIV and schistosomiasis coinfection in African children
Amaya Bustinduy, Charles King, Janet Scott, Sarah Appleton, José Carlos Sousa-Figueiredo, Martha Betson, *J Russell Stothard
HIV/AIDS and schistosomiasis both cause a great disease burden in sub-Saharan Africa, and the two diseases share 
substantial overlap in their epidemiological characteristics. Although disease-specific control interventions are continuing, 
potential synergies in the control efforts for these two diseases have not been investigated. With a focus on children with 
schistosomiasis, we assess the risk for increased HIV transmission, HIV progression, and impaired response to drugs 
when given alongside HIV interventions. A new research agenda tailored to children is needed to better understand the 
interactions of these two diseases and the potential for combined responses. 
Introduction
HIV and schistosomiasis are two of the most widespread 
infections worldwide; nonetheless, their combined effect 
has not been fully delineated, especially in sub-Saharan 
Africa. Although both diseases differ in their presentation, 
manifestations, and treatment, there is substantial geo-
graphical overlap in the poorest countries where 
endemicity is often high (figure 1).1 For example, in 
Ethiopia, Nigeria, South Africa, Zambia, and Zimbabwe, 
adult HIV prevalence ranges from 15% to 28%, and the 
prevalence of schistosomiasis commonly exceeds 50% in 
high-risk rural communities.2 The prevalence of HIV and 
schistosomiasis might be even higher in data-deficient 
areas such as Madagascar or Mozambique.3 
As the HIV pandemic progresses, interventions against 
the increase in HIV-related disease have focused on 
universal access to highly active antiretroviral therapy 
(HAART). Many children in sub-Saharan Africa present 
for care late in their HIV disease progression,4 and there 
are nearly 1000 new cases of paediatric HIV infection 
every day—more than 2·5 million children younger than 
15 years have HIV/AIDS.3 WHO guidance5,6 emphasises 
the importance of prompt diagnosis, treatment, and 
monitoring of HIV in children. Although there is a 
strong commitment from the international community 
to eliminate new childhood HIV infections by 2015, the 
HIV epidemic in sub-Saharan Africa shows little sign of 
abatement.7
Schistosomiasis, either urogenital or intestinal, is a 
chronic inflammatory disease caused by a water-borne 
parasitic blood fluke. In sub-Saharan Africa, 220 million 
people are infected with the parasite, and even more are at 
risk, mainly children.2 Although congenital trans mission 
does not occur, exposure and infection can take place very 
soon after birth, depending on an infant’s environmental 
exposure to parasite-infested water. Until recently, the 
burden of disease from these early exposures was 
overlooked. However, infants and preschool-age children 
(aged 1–5 years) can have active disease8,9 and have poor 
access to deworming treatment because current measures 
are focused on preventive chemotherapy (ie, mass drug 
administration of praziquantel to school-age children 
aged 6–15 years).10 Praziquantel is a safe and affordable 
oral drug that is active against all forms of schistosomiasis 
and can be given by non-medical personnel.11 As new 
information emerges about schistosomiasis in early 
childhood, international policies and practices are 
beginning to respond to this unmet need [A: “inequity” 
has a specific meaning in the global health context, and I 
don’t think the phrase is appropriate here, does “unmet 
need” work, or could you suggest an alternative phrase?].12,13
Identification of disconnects in combined control
HIV control has only a short history, whereas schisto-
somiasis is an old disease,14 for which the inability to 
implement fully integrated preventive strategies because 
of shortfalls in water hygiene and sanitation has led to 
the dominance of preventive chemotherapy as the most 
cost-effective option. Locally applicable and integrated 
interventions tailored to the immediate epidemiological 
setting are desirable. Intricate understanding of the 
transmission biology, epidemiology, and social patterning 
(ie, HIV largely by sexual behaviour and schistosomiasis 
by water contact) of the diseases is needed.
Environmental risk factors for both infections include 
restricted access to safe water, low socioeconomic status, 
and poor educational access.15 HIV transmission risk is 
made up of complex individual behaviours, including 
commercial sex work, intravenous drug use, and various 
unsafe exposures to blood and other bodily fluids; in sub-
Saharan Africa lack of autonomy for women and 
intolerance of male homosexuality are important factors.16 
The social context of schistosomiasis is very different, but 
relates to unsafe exposures that are repeated often during 
domestic tasks or employment. Schistosomiasis is 
typically highly prevalent in fishing communities in which 
opportunities for HIV transmission can also be raised.15,17 
To further complicate control, each disease agent has 
ecological and genetic diversity, with potential to adapt to 
control interventions.18
Although multidisease approaches are being promoted 
by WHO (eg, in management of HIV and malaria), 
related platforms for research and operational control of 
HIV and schistosomiasis simply do not exist.19 There is 
also little room for future optimism because the newly 
created Disease Reference Group of Helminthic 
Infections for the control and elimination of 
helminthiasis in people has not adopted a multiple-
endemic-disease approach within their framework.18 
The first cases of HIV/AIDS in adults were described in 
1981,20 and 5 years lapsed before evidence of routes other 
than sexual transmission emerged and paediatric HIV/
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AIDS was recognised.21 The importance of mother-to-child 
transmission of HIV has only slowly become a public 
health priority.7 Alongside this focus, and with much less 
political advocacy, the case for prevention of schistosomiasis 
in early childhood is only now beginning.8,22–24 Moreover, as 
the subtly disabling morbidities associated with chronic 
schistosomiasis are being better recognised in this age 
group, an imperative for early prevention and control is 
becoming much clearer.25–29
Both diseases are difficult to diagnose in early 
childhood, and studies of HIV and schistosomiasis 
coinfection have been limited to adults.30,31 Paediatric 
studies (except for maternal–child health research) 
typically lag behind those in adults,32 and estimation of 
true burden of disease becomes a challenge because of 
an absence of paediatric diagnostics in resource-poor 
areas (appendix pp xxx [A: please add page numbers for 
table 1 in the appendix].33 
Reconnection of the importance of HIV and 
schistosomiasis coinfection 
Given the potentially overwhelming burden of disease 
caused by dual infection, there are growing efforts to 
study the interactions between HIV and schistosomiasis, 
especially in areas where dual endemicity is most 
prevalent.34–37 Researchers doing experimental studies in 
animals are trying to understand the pathogenesis and 
immune responses when both infections are present.38,39 
Investigators have done clinical studies of responses to 
antiparasitic and antiretroviral therapy for HIV/AIDS 
disease progression.40–43 However, all of these clinical 
studies exclusively targeted individuals older than 
18 years, and thereby overlooked interactions in 
childhood. Attempting to bridge this knowledge gap for 
childhood HIV and schistosomiasis co-infection, we 
reviewed the most relevant epidemiological and experi-
mental studies to develop a conceptual framework 
(figure 2) that identifies the transmission and later mani-
festations of disease in early life alongside current 
recommendations for treatment and integrated national 
control programmes.
Vertical HIV transmission 
The close associations between mothers and their 
unborn children begin an intricate interplay of antigen 
exposure and immune-response modification that 
continues throughout childhood. This interplay might 
lead to increased susceptibility to certain diseases and 
decreased cognition; all of which are known downstream 
effects in children born to women with malaria or 
advanced HIV,26,44,45 but are not yet known in children 
born to women with both HIV and schistosomiasis. HIV 
transmission from infected mothers to children can 
occur through three different routes: intrauterine (5–10% 
[A: of transmissions, or of children with mothers with 
HIV? If transmissions, should the total percentages 
make up 100%?]), during delivery (15–30%), or through 
breastfeeding (5–30%).46 Prepartum maternal helminth 
infections have been linked to increased mother-to-child 
transmission of HIV,47 but lesions from female genital 
schistosomiasis are possibly also important.
WHO advocates universal HAART of all pregnant 
women with HIV, irrespective of their CD4 cell counts, 
but this target is far from a reality in resource-poor sub-
Saharan Africa.7 The lack of consistent HAART for 
pregnant women is one of the major hurdles to 
controlling HIV-transmission. Alongside HAART 
Schistosomiasis
High (prevalence ≥50%)
Moderate (prevalence 10%–49%)
Low (prevalence <10%)
Countries requiring evaluation of schistosomiasis status
to verify if interruption of transmission has been achieved
Non-endemic countries
Not applicable 
HIV
15·0–28·0%
5·0–14·9%
1·0–4·9%
0·5–0·9%
0·1–0·4%
<0·1%
No data available
Adult prevalence (%)
Figure 1: Global adult prevalence of HIV and schistosomiasis 
Different forms of schistosomiasis—urogenital and intestinal—are aggregated including adults and school-age 
children. Dual schistosome infections have not yet been fully estimated nor are prevalences of coinfections with 
HIV known. Data from WHO. 
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antiparasitic treatment (with praziquantel, albendazole, 
or ivermectin) has the possible beneficial effect of 
lowering HIV viral load.48 However, the researchers who 
reported this benefit did not find consistent HAART 
availability for participants, and future studies should 
adopt full treatment of HIV and parasite as standard. 
Differences between children and adults
Extrapolation of knowledge and recommendations from 
adult health interventions into paediatric settings often 
has a so-called little adults approach. For HIV and 
schistosomiasis coinfection, this approach is especially 
flawed in research and policy. For example, children have 
a larger surface-to-volume ratio with higher metabolic 
rate, oxygen consumption, and caloric requirements 
than adults, not only to maintain homoeostasis, but also 
to grow and develop. Typically children need more food 
per kilogram of bodyweight than do adults.49 
Consequently, children are particularly susceptible to any 
growth deficits caused by infections or reduced nutrient 
intake, and growth-faltering states are particularly 
associated with diseases such as HIV/AIDS50 and 
schistosomiasis;27,51 moreover, these infections might 
have synergistic interactions that amplify their individual 
effects.
Drugs are often more widely distributed around 
children’s bodies than in adults and organ blood volumes 
are also higher.52 In schistosomiasis, this pattern could be 
highly relevant if blood flow to the liver is increased, as 
this would lead to swift clearance of praziquantel and a 
strong pharmacodynamic argument to challenge dosing 
recommendations directly extra polated from adults (ie, 
40 mg/kg). Other unanswered questions include how 
HIV infection or continuing HAART might change 
praziquantel efficacy after con sideration that 
praziquantel’s antischistosomal activity is immune-
dependent.53 Thus, the context, timing, and progression 
of each infection is important.
HIV precedes schistosomiasis in children
HIV infection in infants and young children is nearly 
always vertically transmitted; thus HIV infection precedes 
Figure 2: Conceptual framework of the epidemiology of HIV and schistosomiasis coinfection, dual treatment, and proposed control with national guidelines 
and interventions
(A) Proposed pathophysiological mechanism of mother-to-child transmission in pregnant women with one infection (HIV) or two infections (HIV and 
schistosomiasis). (B) Highly active antiretroviral therapy (HAART) and praziquantel treatment guidelines as recommended by WHO. Solid line indicates continued 
treatment. Dotted line indicates treatment based on CD4 cell count and clinical staging [A: ok?]. All pregnant women (M) are encouraged to start HAART (even if not 
indicated on the basis of CD4 cell counts) and to continue throughout. Children (Ch) born to women with HIV are to start HAART for 6 weeks, irrespective of their HIV 
status, since it is a difficult period to ascertain infection, particularly in resource-poor areas. (C) Integrated National Control Programmes should tailor their efforts on 
the basis of in-country prevalence. Programmes should use national health policies that include efforts to control HIV, schistosomiasis, other helminths and 
neglected transmitted diseases, and malaria. Different integrated programmes can include those for maternal–child health, transmission, and ecology of transmission 
that could target social and environmental determinants for all diseases (ie, water sanitation, sexual education and womens’ capacity development, and vector 
control). PZQ=praziquantel. INCP=Integrated National Control Programmes. 
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schistosomiasis (figure 2), whereas in adult-acquired 
infection the reverse is often true (table).54 This distinction 
is very important because the parasitic infection 
(schistosomiasis) in adult-acquired HIV has intrinsically 
different immunopathological and immune-modulating 
effects, which probably shape the pattern of disease. To our 
knowledge, this concept has not been investigated 
clinically; however, investigators of two studies of animals 
have attempted to assess it for retroviral replication and 
worm reduction after praziquantel treatment.38,39 Rhesus 
macaques carrying a latent chronic simian-human 
immunodeficiency virus (SHIV) infection (in analogy with 
HIV) were infected with cercariae of Schistosoma mansoni 
and had an increase in SHIV replication and faster disease 
pro gression than had animals without intestinal schisto-
somiasis.39 In the other study, T-cell-depleted mice infected 
with S mansoni and later treated with two antischistosomal 
drugs (praziquantel and oxamniquine) had little worm 
clearance compared with mice with a healthy immune 
system,38 confirming the important role of host immunity 
in drug action. Thus, if severely immune-suppressed 
people respond to treatment in the same way, particularly 
those with AIDS, then anti schistosomal treatment is likely 
to have reduced effectiveness. Although there are no 
studies of people to corroborate this finding, serial 
retreatment studies of adults with HIV who were at high 
risk of S mansoni suggest that adults with more years of 
parasite exposure in childhood (hence more potential for 
established antiparasite immune responses) have longer 
infection-free periods after praziquantel treatment.55 
However, because of the scarcity of evidence, such 
generalised conjectures should be viewed with caution 
(appendix pp xxx) [A: please add page numbers for table 2 
in appendix].
Schistosomiasis precedes HIV in adults
In endemic areas, as part of daily water contact, 
individuals typically contract schistosomiasis during 
childhood, with subsequent activation of the immune 
system by antigen-specific and non-specific immuno-
modulation biasing towards a T-helper-cell 2 polarity, 
potentially increasing susceptibility to viral and myco-
bacterial infections. Later HIV infection might also 
change the host–parasite immune balance. Epi demi-
ological studies of adults in the Democratic Republic of 
the Congo, Ethiopia, and Kenya show a decrease in 
schistosome-egg excretion for those who acquired HIV 
later in life.34–36 A fully competent T-cell population might 
be needed to augment schistosome-egg excretion, or 
perhaps worm fecundity, although reports of a cohort 
study in Zimbabwe provided evidence to the contrary.37
Nonetheless children’s expected response to egg 
excretion in the presence of HIV is unknown. Results of 
targeted epidemiological surveys have shown a high 
percentage of the infants and preschool-age children 
assessed were shedding eggs,8,9,22,24,56 but studies have not 
investigated the HIV status of examined children. For 
example, children with lower or intermittent egg output 
might have a very light intensity infection or they might 
have compromised immune systems from HIV infection 
(or other immune deficiencies), which impairs efficient 
egg excretion and, for this reason alone, HIV infection 
should be considered as a possible contributing factor to 
rate of egg excretion.
Effect of coinfection on mortality and morbidity 
HIV infection remains a major public health threat in 
sub-Saharan Africa with 1·3 million deaths attributed to 
AIDS every year;3 at least 5% of all disability-adjusted life-
years (DALYs) lost in low-income and middle-income 
countries are believed to be due to HIV/AIDS.57 A 
drawback of the DALY is that the effect of comorbidities 
is overlooked,58 formally bottlenecking the scope of 
health research and intervention programmes. The real 
context of HIV in sub-Saharan Africa is one in which 
children have two or more concurrent parasites in 
addition to their chronic HIV infection. For example, 
results of two paediatric cohort studies in South Africa59 
and Zambia60 identified female sex, young age (younger 
than 2 years), severe wasting, and anaemia as mortality 
risk factors for children with HIV.59,60 Although 
schistosomiasis was not included as a comorbidity in 
either study, it can contribute to wasting and anaemia51,61–64 
and is present in both countries.65,66 The potential 
detrimental synergy between HIV and schistosomiasis 
will be most severe in early childhood due to metabolic 
insults during key periods of growth and development.
Several studies from schistosomiasis-endemic 
countries have shown severe morbidity with end-organ 
fibrosis in children, disorders that were previously 
thought to be clinically relevant only during adulthood.67 
Whether coinfected children are more or less at risk of 
end-organ fibrosis caused by schistosomiasis is 
unknown, but we hypothesise that children with HIV 
have less ultrasound-detectable fibrosis but more liver 
cellular damage, putting them at greater risk of liver 
dysfunction and failure. This damage could be caused by 
T-cell dysregulation, fuelled by HIV infection, preceding 
the onset of schistosomiasis-related hepatosplenic 
disease. This progression is, of course, not the case in 
adults, because liver pathology caused by schistosomiasis 
is already underway when HIV infection is acquired.68,69 
Research to assess the severity of schistosomiasis 
alongside HIV is clearly needed.
Is AIDS linked with schistosomiasis in 
coendemic areas?
HIV Schistosomiasis
Adult Older than 14 years Age 2–5 years 
Child Birth or infancy Younger than 2 years 
Table: Common age of primary infection of HIV and schistosomiasis
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There has been much discussion about whether schisto-
somiasis increases susceptibility to HIV; in Malawi 
where urogenital schistosomiasis is common, an 
increased susceptibility to HIV transmission among 
women has been suggested by the patterns of submucosal 
inflammation found around parasite eggs in cervico-
vaginal biopsy samples.70,71 Studies in Kenya and Uganda, 
where intestinal schistosomiasis is common, have shown 
immune-modulation of anti-HIV responses in patients 
with schistosomiasis, including decreased production of 
interleukins 4 and 10 compared with that in individuals 
without HIV72 and decreased cytolytic CD8 T-cell 
response to viral antigens when both HIV infection and 
schistosomiasis were present.73
The risk of HIV transmission might be increased by 
inflammation in the female genital tract from urogenital 
schistosomiasis, women in Tanzania and Zimbabwe 
with female genital schistosomiais have an increased 
age-adjusted rate of HIV infection compared with those 
without female genital schistosomiais.74–76 The effect of 
maternal female genital schistosomiasis on HIV 
transmission, during parturition for example, is not 
known. Additionally, men with urogential schistosomiasis 
in Madagascar had substantial damage to their 
reproductive tracts,77 with increased amounts of leucocyte 
and proinflammatory cytokine in semen.78 As with other 
proinflammatory sexually transmitted infections, 
urogenital schisto somiasis in both sexes could increase 
HIV transmission as children enter puberty and become 
sexually active.
Babies of mothers who have both HIV and other 
common helminthic infections (lymphatic filariasis, 
urogenital schistosomiasis, and hookworm) during 
pregnancy are more likely to have HIV 1 year after birth 
than are babies born to mothers with HIV alone.47 The 
risk of intrauterine, perinatal, or breast-feeding-related 
mother-to-child HIV transmission might be increased by 
substantial immune-modulation in utero during the 
development of a doubly exposed fetus, rendering the 
baby more susceptible to viral infections.
A more rapid progression of HIV infection with pre-
existing schistosomiasis seems likely because a 17-times-
lower viral inoculum of SHIV was sufficient to infect 
rhesus macaques with intestinal schistosomiasis via 
mucosal exposure, as compared with the dose needed to 
infect controls without intestinal schistosomiasis.79 In 
mice, T-regulatory cell upregulation, which occurs in 
schistosomiasis, can inhibit the ability of CD8 cells to 
control viral replication and, if similar in human beings, 
could potentially increase HIV progression with 
concurrent schistosomiasis.80 Mice with schistosomiasis 
have increased concentrations of arginase-1 in 
macrophages, and the arginase-1 in macrophages and 
neutrophils in individuals with HIV might worsen 
immune hyporesponsiveness, increasing opportunistic 
infections.81,82 The presence of increased HIV receptors 
on CD4 cells in patients with intestinal schistosomiasis 
further raises opportunity for HIV transmission and 
progression.83
Treatment with praziquantel 
The effect of HIV
The effectiveness of praziquantel is dependent on 
adequate blood concentrations of the drug and on 
presence of an intact and robust immune system84—
parasitological cure in T-cell-depleted mice with intestinal 
schistosomiasis is decreased compared with infected 
controls.38 Initial action of praziquantel against adult 
worms is associated with tegumental disruption and later 
synergy with an effective antibody-mediated immune 
attack.84 By contrast, studies of adults with HIV suggest 
that early immune-suppression does not adversely affect 
antischistosomal treatment with praziquantel, with no 
difference noted in parasitological cure rates between 
patients with HIV and those without in Kenya, Zambia, 
and Zimbabwe (appendix pp xxx [A: please add page 
number for table 3 in the appendix. Please supply the 
appendix with table 3 included]).43,85,86 However, effects of 
antiparasitic treatment on HIV-related markers are not 
clear because a 2009 meta-analysis showed some benefit 
for deworming in the prevention of HIV progression 
after pooling randomised trial data.87 When data for 
observational studies were included in the analysis, the 
apparent deworming effect was not as strong.88 Most 
surprisingly perhaps, no study has yet investigated 
treatment of both HIV and schisto somiasis with 
antiretroviral drugs as part of the regimen. In Zimbabwe, 
an unblinded randomised controlled trial showed a 
decrease in viral load and an increase in CD4 cell counts 
among adults who received early praziquantel treatment, 
as compared with those who were treated 3 months after 
diagnosis.89 Results of a double-blind, placebo-controlled, 
trial of multiple helminth coinfections in a cohort of 
pregnant women in Uganda showed no difference in 
viral load between women with HIV given praziquantel 
and those given placebo. However, investigators did 
report a benefit for patients treated with albendazole for 
other helminthic infections, although the prevalence of 
intestinal schistosomiasis in this part of Uganda can be 
considered mild.48 A study in Ethiopia found evidence of a 
relation between deworming and decreased viral load.90 
Conversely, results from two Ugandan studies showed a 
transient increase in viral load and decreased CD4 cell 
counts after treatment, mainly in individuals with severe 
intestinal schisto somiasis,42,91 from a transient host 
immune activation after praziquantel treatment, yielding 
a situation that favours increased viral replication. Other 
results from Kenya, Malawi, Uganda, and Zambia have 
shown no effect of praziquantel on HIV viral markers.40,92,93
Use of praziquantel in children
The dosage for praziquantel in children (ie, at 40 mg/kg) 
is a direct extrapolation from adults, and is probably 
flawed because no information about praziquantel 
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pharma cokinetics and pharmacodynamics in young 
children is available. Nonetheless, studies indicate 
efficacy and safety on-the-ground with use of a 
praziquantel dosing pole, which allocates treatment on 
the basis of childrens’ height [A: OK?].9,12,94 However, 
evidence from Uganda95 has raised questions about 
recommended dosing, which might be inadequate for 
the metabolism of pre-school-age children and about 
whether chlidren’s immune systems are sufficiently 
developed to provide potent parasite clearance. This 
effect on parasite clearance could be worsened by 
concurrent HIV infection or some other congenital or 
acquired immune deficiency.
Extrapolation of dose by weight from adults is 
particularly problematic because blood volumes, meta-
bolic rates, and extracellular volumes are better correlated 
with body surface area. As a result, drug doses normalised 
to the weight of adults can result in lower doses in young 
children than when normalised to body surface area.96 
Developmental changes are also important; particularly 
pertinent to praziquantel is the maturation of drug 
metabolism because the fetal liver contains only 30–40% 
of the CYP450 detoxification system content of adults, 
which typically ascends to a peak by age 10 years.97 These 
reduced enzyme concentrations might suggest slower 
drug clearance from the bloodstream in children, which is 
consistent with observations that drug concentrations are 
generally reported as higher in children than in adults.98 
An era of community chemotherapy: drug–drug 
interactions
With the roll-out of HAART and increasing use of 
praziquantel in early childhood,99 there might be 
substantial benefit to treat both diseases simultaneously 
and as early as possible; however, some further 
consideration of drug interactions and side-effects would 
be advisable because of the many potential interactions 
between antiretroviral therapy and antiparasitic drugs. 
The cytochrome P450 super-family of enzymes is central 
to drug metabolism and drug–drug interactions, 
particularly praziquantel.100 Praziquantel is rapidly 
absorbed and has more than 80% bioavailability after oral 
administration,101 with drug clearance predominantly 
occurring by first-pass meta bolism of CYP1A2, CYP2C19, 
and CYP3A4, with a dominance of CYP3A.102,103 Based on 
knowledge of drug metabolism, the expected effects of 
clinicians giving both HAART and praziquantel will 
probably differ dependent on which antiretroviral therapy 
drugs are used. For example, decreased praziquantel 
concentrations could occur if given concurrently with 
non-nucleoside reverse transcriptase inhibitors 
nevirapine or efavirenz, so-called HIV backbone 
treatments. These drugs are CYP450 inducers. 
Coadministration of praziquantel with protease 
inhibitors, which tend to inhibit CYP450 metabolism, 
could lead to increased praziquantel concentrations;104 
thus, well designed studies of paediatric pharmacokinetics 
are needed to ensure safe and effective dosing when 
drugs are given concurrently.
Other drugs commonly used in sub-Saharan Africa are 
artemisinin-combination drugs and quinine derivatives 
for malaria, but based on their liver enzyme 
metabolism,105,106 neither is unlikely to affect praziquantel 
metabolism when given concomitantly. Antituberculous 
treatments (rifampicin, isoniazid, and clarithromycin) 
might have an effect on circulating praziquantel 
concentrations. Rifampicin is a potent inducer of 
CYP450, particularly CYP2C19 and CYP3A4, and in 
theory, this action could reduce circulating praziquantel 
concentrations.103 Isoniazid and clarithromycin might 
increase praziquantel circulating concentrations.107–109 
Clarithromycin is recommended for multidrug-resistant 
infections, but if treatment with praziquantel was judged 
essential—and, as an open conjecture, rifampicin could 
be stopped 4 weeks before praziquantel was given and 
then reinstated a day after the praziquantel regimen—
then praziquantel might be able to be given, although 
repercussions of this regimen are not known and 
ethically questionable [A: OK? JS’s corrections were 
unclear here. Please clarify].107
Immune reconstitution inflammatory syndrome
Immune reconstitution inflammatory syndrome, more 
recently referred to as immune reconstitution disease, is 
a well known disorder that can occur after initiation of 
HAART in some individuals. Immune reconstitution 
disease is a collection of inflammatory disorders 
associated with paradoxical worsening of existing 
infectious processes, particularly opportunistic infections 
of HIV/AIDS.110 Clinicians are reporting an increasing 
number of immune reconstitution disease cases in 
association with parasitic diseases, with flare-ups of 
reactivating schistosomiasis being noted–evidenced by 
raised eosinophilia, hepatosplenomegaly, and colitis with 
polyposis.45
In Zimbabwe, results of a 2008 study show significant 
decreases in soluble tumour necrosis factor receptor II (a 
cytokine-associated marker linked with systemic 
inflammation) among patients with both HIV and 
schisto somiasis after they were given praziquantel.41 This 
finding suggests a reduction in inflammatory responses 
after praziquantel, which might lead to decreased HIV 
viral replication and even attenuate the risk of immune 
reconstitution disease after HAART. Because no studies 
have been done in patients given HAART, this sphere 
remains to be explored in all age groups.
HIV and schistosomiasis coinfection and 
childhood vaccinations
After the expanded programme of vaccination, global 
vaccine coverage for children is increasing every year,19 
whereas knowledge for the effects of coexisting childhood 
morbidities on response to vaccines is lagging behind, 
restricting vaccines’ optimum effectiveness in on-the-
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ground settings. Although safe, vaccination in children 
with HIV is less immunogenic than in children without 
HIV,111–113 and children with HIV who do achieve protective 
antibody titres can have a more rapid waning of vaccine-
induced immunity.114
Children born to women who have parasitic diseases, 
including schistosomiasis, and have a decreased response 
to certain childhood vaccinations (eg, BCG115,116). A 2011 
randomised controlled trial in Uganda showed no 
association between single praziquantel or albendazole 
treatment of late-term pregnant women and the response 
of their infants to BCG;117 it is unlikely that one maternal 
dose of praziquantel can erase fetal immune sensitisation 
to schistosome antigens. However, the question remains 
as to whether maternal parasite infection, and then 
immune-skewing by HIV, modifies or exacerbates disease 
among children who then acquire schistosomiasis early in 
life, and whether HIV and schistosomiasis have combined 
effects on the efficacy of later childhood vaccinations—all 
of these events can also be set against pubertal hormonal 
production and its potential protection against 
schistosomiasis.118,119
Delineating a research agenda 
As we have stated, there are several gaps in [A: We would 
like to avoid use of our because of majestic plurals. OK?] 
knowledge about HIV and schistosomiasis coinfection in 
children, which is rather staggering. Within the planning 
context for future integrated health interventions, we 
firmly believe that there is a global duty to address 
promptly the disparity between paediatric and adult 
research and, as conceptual guidance, we suggest a 
timeline for future paediatric HIV and schistosomiasis 
research, delineated into key developmental periods of 
the child (figure 3).
Before birth, there should be better documentation of 
the intricate relation between HIV and concurrent 
helminthiasis in mothers and unborn children, including 
efforts to develop non-invasive imagery methods or 
assays for detection of female genital schistosomiasis to 
clarify the at-risk population. Pregnant women with 
female genital schistosomiasis should receive 
praziquantel and rates of HIV transmission from treated 
mothers to children should be recorded. The effect of 
untreated vertically transmitted HIV in children who 
contract schistosomiasis at an early age should be 
investigated along with their rate of progression to AIDS. 
The response to immunisations in children coinfected 
with HIV and schistosomiasis should be studied, with 
observation of children born to women with schisto-
somiasis. Researchers should investigate the extent of 
fetal immune priming and modulation during the 
antenatal period and how this priming affects risk of 
schistosomiasis disease and HIV progression later in life.
For children, the timing and successful occurrence of 
key stages as they progressively gain independence from 
their mothers is important. Interactions between HIV 
and schistosomiasis in causative mechanisms of 
anaemia, growth, retardation, decreased cognition, and 
decrease in overall quality of life need to be elucidated. 
Pharmacokinetics and pharmacodynamics of 
praziquantel efficacy in children should be investigated 
in field settings, as should drug–drug interactions of 
antiparasitic drugs used in preventive chemotherapy 
alongside HAART and antituberculous drugs. 
Investigators should more precisely measure the 
physical changes and psychological challenges to attain 
wellbeing for older children and adolescents with chronic 
diseases such as HIV and schistosomiasis by doing 
culturally sensitive studies of issues surrounding the 
beginning of sexual activity and minimisation of further 
risks of HIV transmission. Non-invasive methods for 
Immune responses in children vertically infected with HIV followed by Schistosoma spp infection
Perinatal mortality associated with vertical HIV 
transmission and severe immunosuppression 
with early schistosomiasis
Impaired growth and development
Paediatric quality-of-life assessment
Cognitive performance
Maternal–child HIV
transmission risks
(ie, FUS)
Immune-modulations in
fetus from mother with
HIV or schistosomiasis
Evolving PZQ pharmacokinetics and pharmacodynamics and performance
Drug–drug interactions of PZQ with ARVs and anti-malarials
Early schistosomiasis disease in children with HIV and HIV-exposed children
Progression to AIDS alongside concurrent schistosomiasis
Response to childhood vaccinations in children with HIV–schistosomiasis
New diagnostic methods for FUS
Psychosocial hurdles affecting ART
compliance and initiation of sexuality
Interactions with secondary hormones
Prenatal Infants
(birth–1 years)
Preschool age child
(aged 2–5 years)
School-age child
(aged 6–13 years)
Adolescents
(older than 14 years)
Early interactions 
in infants with HIV 
or early Schistosoma 
exposure
Figure 3: Suggested topics for research of paediatric HIV and schistosomiasis infection in dual endemic areas of sub-Saharan Africa
FUS=female genital schistosomiasis. PZQ=praziquantel. ARV=antiretrovirals.
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detection of genital schistosomiasis in both sexes and 
clinical staging schedules for disease management are 
needed. Pubertal hormonal production and its potential 
protection against schistosomiasis progression and 
reinfection rates should be studied. Social determinants 
of health encompassing behavioural and psychosocial 
problems should be recorded to ensure the development 
and application of tailored interventions.
Conclusion 
Provision of optimum public health care for paired 
management of HIV and schistosomiasis in sub-Saharan 
Africa might be more than a decade away. Failure to 
develop and implement a realistic research agenda for 
infected children will result in the neglect of the youngest 
children who might be at particular risk for increased 
HIV transmission, HIV progression, and impaired 
response to drugs. We hope that this review will stimulate 
a collective agenda to ensure that real progress will be 
made in the long-term management of paediatric HIV 
and schistosomiasis coinfection.
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